Artificial intelligence in the service of intrauterine insemination and timed intercourse in spontaneous cycles.


Journal

Fertility and sterility
ISSN: 1556-5653
Titre abrégé: Fertil Steril
Pays: United States
ID NLM: 0372772

Informations de publication

Date de publication:
11 2023
Historique:
received: 04 02 2023
revised: 06 07 2023
accepted: 18 07 2023
medline: 30 10 2023
pubmed: 26 7 2023
entrez: 25 7 2023
Statut: ppublish

Résumé

To develop a machine learning model designed to predict the time of ovulation and optimal fertilization window for performing intrauterine insemination or timed intercourse (TI) in natural cycles. A retrospective cohort study. A large in vitro fertilization unit. Patients who underwent 2,467 natural cycle-frozen embryo transfer cycles between 2018 and 2022. None. Prediction accuracy of the optimal day for performing insemination or TI. The data set was split into a training set including 1,864 cycles and 2 test sets. In the test sets, ovulation was determined according to either expert opinion, with 2 independent fertility experts determining ovulation day ("expert") (496 cycles), or according to the disappearance of the leading follicle between 2 consecutive days' ultrasound examinations ("certain ovulation") (107 cycles). Two algorithms were trained: an NGBoost machine learning model estimating the probability of ovulation occurring on each cycle day and a treatment management algorithm using the learning model to determine an optimal insemination day or whether another blood test should be performed. The estradiol progesterone and luteinizing hormone levels on the last test performed were the most influential features used by the model. The mean numbers of tests were 2.78 and 2.85 for the "certain ovulation" and "expert" test sets, respectively. In the "expert" set, the algorithm correctly predicted ovulation and suggested day 1 or 2 for performing insemination in 92.9% of the cases. In 2.9%, the algorithm predicted a "miss," meaning that the last test day was already ovulation day or beyond, suggesting avoiding performing insemination. In 4.2%, the algorithm predicted an "error," suggesting performing insemination when in fact it would have been performed on a nonoptimal day (0 or -3). The "certain ovulation" set had similar results. To our knowledge, this is the first study to implement a machine learning model, on the basis of the blood tests only, for scheduling insemination or TI with high accuracy, attributed to the capability of the algorithm to integrate multiple factors and not rely solely on the luteinizing hormone surge. Introducing the capabilities of the model may improve the accuracy and efficiency of ovulation prediction and increase the chance of conception. HMC-0008-21.

Identifiants

pubmed: 37490977
pii: S0015-0282(23)00697-0
doi: 10.1016/j.fertnstert.2023.07.008
pii:
doi:

Substances chimiques

Luteinizing Hormone 9002-67-9

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1004-1012

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2023 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests M.Y. has nothing to disclose. A.L. is a shareholder and board member of FertilAI LTD. M.B. is a shareholder and board member of FertilAI LTD. R.H. is a shareholder and board member of FertilAI LTD. S.R. is an employee of FertilAI LTD. E.M. is a shareholder and board member of FertilAI LTD. A.H. is a shareholder and board member of FertilAI LTD.

Auteurs

Michal Youngster (M)

IVF Unit, Department of Obstetrics and Gynecology, Shamir Medical Center, Zerifin, Israel; Sackler School of Medicine, Tel Aviv University, Tel-Aviv, Israel. Electronic address: michalyo@gmail.com.

Almog Luz (A)

FertilAi, Ramat Gan, Israel.

Micha Baum (M)

Sackler School of Medicine, Tel Aviv University, Tel-Aviv, Israel; FertilAi, Ramat Gan, Israel; IVF Unit, Herzliya Medical Centre, Herzliya, Israel; IVF Unit, Department of Obstetrics and Gynecology, Sheba Medical Center, Ramat-Gan, Israel.

Rohi Hourvitz (R)

FertilAi, Ramat Gan, Israel.

Shachar Reuvenny (S)

FertilAi, Ramat Gan, Israel.

Ettie Maman (E)

Sackler School of Medicine, Tel Aviv University, Tel-Aviv, Israel; FertilAi, Ramat Gan, Israel; IVF Unit, Herzliya Medical Centre, Herzliya, Israel; IVF Unit, Department of Obstetrics and Gynecology, Sheba Medical Center, Ramat-Gan, Israel.

Ariel Hourvitz (A)

IVF Unit, Department of Obstetrics and Gynecology, Shamir Medical Center, Zerifin, Israel; Sackler School of Medicine, Tel Aviv University, Tel-Aviv, Israel; FertilAi, Ramat Gan, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH